I
Description
Norwegian pharmaceutical company founded in 2020 in Oslo. Dedicated to developing needle-free transdermal insulin for diabetic patients. Investigational product INS-2301 is a transdermal insulin spray with potential to replace needle-based administration. Completed a 25 million NOK funding round to begin clinical trials. Member of Legemiddelindustrien (Norway's Association of the Pharmaceutical Industry).